How to Add Fingerprint Authentication to Your Windows 11 Computer Your email has been sent You can easily add a fingerprint reader to your computer if one isn't already built in. If you’ve ...

Twelve days after police lifted fingerprints from the Bandra residence of Saif Ali Khan, it remains unclear whether they were left behind by Shariful Islam alias Vijay Das, the man who has been ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week ...

Executive Director and Co-Founder of the Not-For-Profit U.S. Biosimilars Forum PBM reform did not make it into the final continuing resolution this past December. Now, time is of the essence for ...

Celltrion Inc.’s biosimilar versions of Amgen Inc.’s blockbuster bone-strengthening drugs Prolia and Xgeva are blocked in the US until June 1 as part of a settlement agreement, according to a filing ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch. Celltrion’s Stelara biosimilar ustekinumab ...

Known as AVT05, the Alvotech medication is a proposed biosimilar to Simponi, prescribed to treat various inflammatory conditions. The FDA is set to review the Biologics License Applications (BLAs) for ...

Saif Ali Khan Stabbing Case: A new twist has been reported in the actor's attack case. Earlier, it was reported that Mumbai Police collected 19 fingerprints from the actor's Bandra residence. Now, it ...

In a massive development in the Saif Ali Khan’s attack case, the fingerprints found at the actor’s residence do not match the samples of Shariful Islam Shehzad, a Bangladeshi national who was arrested ...

The 19 sets of fingerprints collected from actor Saif Ali Khan's residence after the attempted burglary and knife attack on him do not match the fingerprints of the accused Shariful Islam ...

In 2025, the three largest pharmacy benefit managers are largely rejecting biosimilars from their formularies, with the exception of their own private-label medicines, Drug Channels reported Jan. 22.

Surveying the next 12 months, J&J expects to chart roughly 3% sales growth to $91.3 billion in 2025 by “overcoming headwinds associated with U.S. biosimilar entries for Stelara,” as well as ...